News related to Remicade (Infliximab) and/or conditions it is approved for
Remicade Phase 3 data show long-term psoriasis response
Source: The Doctors Lounge - Dermatology
Findings from two Phase 3 studies show high-level, sustained response with maintenance therapy.
Anti-Tumor Necrosis Factor Treatment Does Not Increase Cancer Risk In RA Patients
Source: Arthritis / Rheumatology News From Medical News Today [2009.10.30]
A recent study by Swedish researchers found that rheumatoid arthritis (RA) patients did not experience an elevated cancer risk in the first 6 years after starting anti-tumor necrosis factor (TNF) therapy. The research team, led by Johan Askling, M.D., Ph.D., from Karolinska University Hospital in Stockholm, Sweden assessed the short-term and medium-term cancer risk for RA patients using anti-TNF therapies: infliximab, adalimumab, and etanercept.
Need For Surgery Almost Halved By Ulcerative Colitis Treatment
Source: Irritable-Bowel Syndrome News From Medical News Today [2009.10.03]
A new study led by Mayo Clinic researchers has found that ulcerative colitis patients had a 41 percent reduction in colectomy after a year when treated with infliximab, according to a study published in the October 2009 issue of Gastroenterology. Ulcerative colitis, an inflammatory bowel disease (IBD) that causes chronic inflammation of the colon, is characterized by abdominal pain and diarrhea.
|
